Enhanced efficacy of sequential administration of Albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT.
Identifieur interne : 000F48 ( PubMed/Checkpoint ); précédent : 000F47; suivant : 000F49Enhanced efficacy of sequential administration of Albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT.
Auteurs : R L De Britto [Inde] ; P. Vanamail [Inde] ; T. Sankari [Inde] ; G. Vijayalakshmi [Inde] ; L K Das [Inde] ; S P Pani [Malaisie]Source :
- Tropical biomedicine [ 0127-5720 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Albendazole (administration et posologie), Animaux, Association de médicaments (), Diéthylcarbamazine (administration et posologie), Doxycycline (administration et posologie), Femelle, Filaricides (administration et posologie), Filarioses (traitement médicamenteux), Humains, Mâle, Méthode en double aveugle, Résultat thérapeutique, Wuchereria bancrofti (), Études de suivi.
- MESH :
- administration et posologie : Albendazole, Diéthylcarbamazine, Doxycycline, Filaricides.
- traitement médicamenteux : Filarioses.
- Adulte, Adulte d'âge moyen, Animaux, Association de médicaments, Femelle, Humains, Mâle, Méthode en double aveugle, Résultat thérapeutique, Wuchereria bancrofti, Études de suivi.
English descriptors
- KwdEn :
- Adult, Albendazole (administration & dosage), Animals, Diethylcarbamazine (administration & dosage), Double-Blind Method, Doxycycline (administration & dosage), Drug Therapy, Combination (methods), Female, Filariasis (drug therapy), Filaricides (administration & dosage), Follow-Up Studies, Humans, Male, Middle Aged, Treatment Outcome, Wuchereria bancrofti (drug effects).
- MESH :
- chemical , administration & dosage : Albendazole, Diethylcarbamazine, Doxycycline, Filaricides.
- drug effects : Wuchereria bancrofti.
- drug therapy : Filariasis.
- methods : Drug Therapy, Combination.
- Adult, Animals, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
Till today, there is no effective treatment protocol for the complete clearance of Wuchereria bancrofti (W.b) infection that causes secondary lymphoedema. In a double blind randomized control trial (RCT), 146 asymptomatic W. b infected individuals were randomly assigned to one of the four regimens for 12 days, DEC 300 mg + Doxycycline 100 mg coadministration or DEC 300 mg + Albendazole 400 mg co-administration or DEC 300 mg + Albendazole 400 mg sequential administration or control regimen DEC 300 mg and were followed up at 13, 26 and 52 weeks post-treatment for the clearance of infection. At intake, there was no significant variation in mf counts (F(3,137)=0.044; P=0.988) and antigen levels (F(3,137)=1.433; P=0.236) between the regimens. Primary outcome analysis showed that DEC + Albendazole sequential administration has an enhanced efficacy over DEC + Albendazole co-administration (80.6 Vs 64.7%), and this regimen is significantly different when compared to DEC + doxycycline co-administration and control (P<0.05), in clearing microfilaria in 13 weeks. Secondary outcome analysis showed that, all the trial regimens were comparable to control regimen in clearing antigen (F(3, 109)=0.405; P=0.750). Therefore, DEC + Albendazole sequential administration appears to be a better option for rapid clearance of W. b microfilariae in 13 weeks time. (Clinical trials.gov identifier - NCT02005653).
PubMed: 26691247
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26691247Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Enhanced efficacy of sequential administration of Albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT.</title><author><name sortKey="De Britto, R L" sort="De Britto, R L" uniqKey="De Britto R" first="R L" last="De Britto">R L De Britto</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry</wicri:regionArea><wicri:noRegion>Pondicherry</wicri:noRegion></affiliation></author><author><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P" last="Vanamail">P. Vanamail</name><affiliation wicri:level="1"><nlm:affiliation>All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>All India Institute of Medical Sciences, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Sankari, T" sort="Sankari, T" uniqKey="Sankari T" first="T" last="Sankari">T. Sankari</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Microbiology & Immunology, Vector Control Research Centre, Pondicherry, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Unit of Microbiology & Immunology, Vector Control Research Centre, Pondicherry</wicri:regionArea><wicri:noRegion>Pondicherry</wicri:noRegion></affiliation></author><author><name sortKey="Vijayalakshmi, G" sort="Vijayalakshmi, G" uniqKey="Vijayalakshmi G" first="G" last="Vijayalakshmi">G. Vijayalakshmi</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry</wicri:regionArea><wicri:noRegion>Pondicherry</wicri:noRegion></affiliation></author><author><name sortKey="Das, L K" sort="Das, L K" uniqKey="Das L" first="L K" last="Das">L K Das</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry</wicri:regionArea><wicri:noRegion>Pondicherry</wicri:noRegion></affiliation></author><author><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S P" last="Pani">S P Pani</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, Quest International University Perak, Malaysia.</nlm:affiliation><country xml:lang="fr">Malaisie</country><wicri:regionArea>Faculty of Medicine, Quest International University Perak</wicri:regionArea><wicri:noRegion>Quest International University Perak</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26691247</idno><idno type="pmid">26691247</idno><idno type="wicri:Area/PubMed/Corpus">000A95</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A95</idno><idno type="wicri:Area/PubMed/Curation">000A95</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A95</idno><idno type="wicri:Area/PubMed/Checkpoint">000A95</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A95</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Enhanced efficacy of sequential administration of Albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT.</title><author><name sortKey="De Britto, R L" sort="De Britto, R L" uniqKey="De Britto R" first="R L" last="De Britto">R L De Britto</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry</wicri:regionArea><wicri:noRegion>Pondicherry</wicri:noRegion></affiliation></author><author><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P" last="Vanamail">P. Vanamail</name><affiliation wicri:level="1"><nlm:affiliation>All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>All India Institute of Medical Sciences, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Sankari, T" sort="Sankari, T" uniqKey="Sankari T" first="T" last="Sankari">T. Sankari</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Microbiology & Immunology, Vector Control Research Centre, Pondicherry, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Unit of Microbiology & Immunology, Vector Control Research Centre, Pondicherry</wicri:regionArea><wicri:noRegion>Pondicherry</wicri:noRegion></affiliation></author><author><name sortKey="Vijayalakshmi, G" sort="Vijayalakshmi, G" uniqKey="Vijayalakshmi G" first="G" last="Vijayalakshmi">G. Vijayalakshmi</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry</wicri:regionArea><wicri:noRegion>Pondicherry</wicri:noRegion></affiliation></author><author><name sortKey="Das, L K" sort="Das, L K" uniqKey="Das L" first="L K" last="Das">L K Das</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry</wicri:regionArea><wicri:noRegion>Pondicherry</wicri:noRegion></affiliation></author><author><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S P" last="Pani">S P Pani</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, Quest International University Perak, Malaysia.</nlm:affiliation><country xml:lang="fr">Malaisie</country><wicri:regionArea>Faculty of Medicine, Quest International University Perak</wicri:regionArea><wicri:noRegion>Quest International University Perak</wicri:noRegion></affiliation></author></analytic><series><title level="j">Tropical biomedicine</title><idno type="ISSN">0127-5720</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Albendazole (administration & dosage)</term><term>Animals</term><term>Diethylcarbamazine (administration & dosage)</term><term>Double-Blind Method</term><term>Doxycycline (administration & dosage)</term><term>Drug Therapy, Combination (methods)</term><term>Female</term><term>Filariasis (drug therapy)</term><term>Filaricides (administration & dosage)</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Wuchereria bancrofti (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Albendazole (administration et posologie)</term><term>Animaux</term><term>Association de médicaments ()</term><term>Diéthylcarbamazine (administration et posologie)</term><term>Doxycycline (administration et posologie)</term><term>Femelle</term><term>Filaricides (administration et posologie)</term><term>Filarioses (traitement médicamenteux)</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Wuchereria bancrofti ()</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Doxycycline</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term><term>Diéthylcarbamazine</term><term>Doxycycline</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Filariasis</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy, Combination</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filarioses</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Animals</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Association de médicaments</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Wuchereria bancrofti</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Till today, there is no effective treatment protocol for the complete clearance of Wuchereria bancrofti (W.b) infection that causes secondary lymphoedema. In a double blind randomized control trial (RCT), 146 asymptomatic W. b infected individuals were randomly assigned to one of the four regimens for 12 days, DEC 300 mg + Doxycycline 100 mg coadministration or DEC 300 mg + Albendazole 400 mg co-administration or DEC 300 mg + Albendazole 400 mg sequential administration or control regimen DEC 300 mg and were followed up at 13, 26 and 52 weeks post-treatment for the clearance of infection. At intake, there was no significant variation in mf counts (F(3,137)=0.044; P=0.988) and antigen levels (F(3,137)=1.433; P=0.236) between the regimens. Primary outcome analysis showed that DEC + Albendazole sequential administration has an enhanced efficacy over DEC + Albendazole co-administration (80.6 Vs 64.7%), and this regimen is significantly different when compared to DEC + doxycycline co-administration and control (P<0.05), in clearing microfilaria in 13 weeks. Secondary outcome analysis showed that, all the trial regimens were comparable to control regimen in clearing antigen (F(3, 109)=0.405; P=0.750). Therefore, DEC + Albendazole sequential administration appears to be a better option for rapid clearance of W. b microfilariae in 13 weeks time. (Clinical trials.gov identifier - NCT02005653).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26691247</PMID><DateCreated><Year>2015</Year><Month>12</Month><Day>22</Day></DateCreated><DateCompleted><Year>2016</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0127-5720</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Tropical biomedicine</Title><ISOAbbreviation>Trop Biomed</ISOAbbreviation></Journal><ArticleTitle>Enhanced efficacy of sequential administration of Albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT.</ArticleTitle><Pagination><MedlinePgn>198-209</MedlinePgn></Pagination><Abstract><AbstractText>Till today, there is no effective treatment protocol for the complete clearance of Wuchereria bancrofti (W.b) infection that causes secondary lymphoedema. In a double blind randomized control trial (RCT), 146 asymptomatic W. b infected individuals were randomly assigned to one of the four regimens for 12 days, DEC 300 mg + Doxycycline 100 mg coadministration or DEC 300 mg + Albendazole 400 mg co-administration or DEC 300 mg + Albendazole 400 mg sequential administration or control regimen DEC 300 mg and were followed up at 13, 26 and 52 weeks post-treatment for the clearance of infection. At intake, there was no significant variation in mf counts (F(3,137)=0.044; P=0.988) and antigen levels (F(3,137)=1.433; P=0.236) between the regimens. Primary outcome analysis showed that DEC + Albendazole sequential administration has an enhanced efficacy over DEC + Albendazole co-administration (80.6 Vs 64.7%), and this regimen is significantly different when compared to DEC + doxycycline co-administration and control (P<0.05), in clearing microfilaria in 13 weeks. Secondary outcome analysis showed that, all the trial regimens were comparable to control regimen in clearing antigen (F(3, 109)=0.405; P=0.750). Therefore, DEC + Albendazole sequential administration appears to be a better option for rapid clearance of W. b microfilariae in 13 weeks time. (Clinical trials.gov identifier - NCT02005653).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Britto</LastName><ForeName>R L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanamail</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankari</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Unit of Microbiology & Immunology, Vector Control Research Centre, Pondicherry, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vijayalakshmi</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>L K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pani</LastName><ForeName>S P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Quest International University Perak, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02005653</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Malaysia</Country><MedlineTA>Trop Biomed</MedlineTA><NlmUniqueID>8507086</NlmUniqueID><ISSNLinking>0127-5720</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical><Chemical><RegistryNumber>F4216019LN</RegistryNumber><NameOfSubstance UI="D015766">Albendazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>N12000U13O</RegistryNumber><NameOfSubstance UI="D004318">Doxycycline</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004318" MajorTopicYN="N">Doxycycline</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005368" MajorTopicYN="N">Filariasis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014958" MajorTopicYN="N">Wuchereria bancrofti</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26691247</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Inde</li><li>Malaisie</li></country></list><tree><country name="Inde"><noRegion><name sortKey="De Britto, R L" sort="De Britto, R L" uniqKey="De Britto R" first="R L" last="De Britto">R L De Britto</name></noRegion><name sortKey="Das, L K" sort="Das, L K" uniqKey="Das L" first="L K" last="Das">L K Das</name><name sortKey="Sankari, T" sort="Sankari, T" uniqKey="Sankari T" first="T" last="Sankari">T. Sankari</name><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P" last="Vanamail">P. Vanamail</name><name sortKey="Vijayalakshmi, G" sort="Vijayalakshmi, G" uniqKey="Vijayalakshmi G" first="G" last="Vijayalakshmi">G. Vijayalakshmi</name></country><country name="Malaisie"><noRegion><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S P" last="Pani">S P Pani</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000F48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26691247
|texte= Enhanced efficacy of sequential administration of Albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26691247" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |